



Product Information

Product ID C1668

CAS No. 143201-11-0

Chemical Name (3R,5S,6E)-7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid

Synonym Baycol, Lipobay, Rivastatin

Formula C₂₆H₃₃FNO₅Na

Formula Wt. 481.53

Melting Point


Purity ≥98%

Solubility Soluble in water.

Store Temp -20° C

Ship Temp Ambient

Description Cerivastatin is an inhibitor of HMG-CoA reductase that exhibits anti-hyperlipidemic, anti-atherosclerotic, anti-fibrotic, and anti-inflammatory activities. Cerivastatin has been used clinically to lower cholesterol and treat cardiovascular disease, but has since been withdrawn from the market due to associations with the development of rhabdomyolysis. In vitro, cerivastatin decreases production and activation of IL-6, AP-1, and NF-κB. In hepatocytes, this compound decreases TNF-α-induced production of PAI-1, preventing atherosclerosis and fibrosis.



Bulk quantities available upon request

Product ID	Size
C1668	5 mg
C1668	10 mg
C1668	25 mg

References Takeshita Y, Takamura T, Hamaguchi E, et al. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line. *Metabolism*. 2006 Nov;55(11):1464-72. PMID: 17046548.

Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. *Fundam Clin Pharmacol*. 2005 Feb;19(1):117-25. PMID: 15660968.

Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. *Am Heart J*. 2004 Jun;147(6):956-65. PMID: 15199341.

Viedt C, Shen W, Fei J, et al. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. *Basic Res Cardiol*. 2003 Nov;98(6):353-61. PMID: 14556080.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.